Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Tighter glucose control is known to reduce the risk of complications of diabetes like cardiovascular ... currently compatible with three of Lilly's insulin products, including Humalog and Lyumjev ...

Minnesota Attorney General Keith Ellison announced on Monday that a settlement has been reached Novo Nordisk over the high ...

Eli Lilly and Company discovers ... and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt ...

Minnesotans prescribed insulin won’t pay more than $35 per month for it, after the conclusion of a lawsuit against three ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as the drugmaker struggled to forecast demand for its popular weight-loss and diabetes shots for the second quarter ...

products were taken off the shortage list in October. Some of Novo Nordisk's (NVO) semaglutide formulations remain on the list. Lilly (LLY) markets tirzepatide for diabetes as Mounjaro and for ...

Global pharma major Lupin Limited announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin ...